Effectiveness of ustekinumab and improvement in real-world work productivity and associated indirect costs in patients with moderate-severe Crohn's disease in the United States of America.

BACKGROUND: Ustekinumab (UST) reduced symptom prevalence, work productivity loss (WPL) and indirect costs among Crohn's disease (CD) patients in clinical trial. However, little is known on real-world effectiveness of UST in relation to symptom preval…

Preview only. Read the full abstract at the source